Metabolic Dysregulation and Cancer Risk Program: A Transdisciplinary Approach to Obesity-Associated Cancer Research

Metabolic Dysregulation and Cancer Risk Program Banner

Need Help?

Have questions about this topic or need additional assistance?

Contact Our Staff
Contact Us

Tram Kim Lam, Ph.D., M.P.H.
Program Director, Environmental Epidemiology Branch
lamt@mail.nih.gov

Phil Daschner, M.Sc.
Program Director, Division of Cancer Biology
daschnep@mail.nih.gov

Edward Sauter, M.D., Ph.D.
Medical and Program Officer, Breast and Gynecologic Cancer Research Group (BGCRG), Division of Cancer Prevention
edward.sauter@nih.gov

Overview

The overall purpose of NCI’s Metabolic Dysregulation and Cancer Risk Program is to enhance knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation, and increased cancer risk in individuals and identify mechanisms that will enhance cancer risk prediction, screening for high-risk individuals in clinical settings, and potential targets for preventive and therapeutic interventions.

For the purposes of the funding opportunities that will support this research, metabolic dysregulation is defined as alterations in glucose utilization and storage, insulin sensitivity, and/or lipid metabolism.

This program will be supported by two funding opportunity announcements (FOAs): one will support multiple research project grants and another will support a coordinating center.

Funding Opportunities

NCI-sponsored Funding Opportunity Announcements (FOAs) related to metabolic dysregulation and risk of cancer include:

  • Metabolic Dysregulation and Cancer Risk Program, Research Grants: A Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional) – expires October 7, 2021
  • Coordinating Center for the Metabolic Dysregulation and Cancer Risk Program: A Transdisciplinary Approach to Obesity-Associated Research (U24 Clinical Trial Not Allowed) – expires October 7, 2021

Pre-Application Webinar

  • Pre-application Webinar for Metabolic Dysregulation and Cancer Risk Program: a Transdisciplinary Approach to Obesity-Associated Research - RFA-CA-21-021 and RFA-CA-21-022 (August 2021)